Is Martin Shkreli the picture of a new breed of pharmaceutical entrepreneur who is as committed to creating a better class of drugs to fight critical diseases as he is to ensuring his company is profitable? Or is he the poster boy for all that's wrong in the health care industry as he buys a drug that's vital for some very sick people and increases its cost by more than 5,000 percent? Those are questions being asked today following a Friday story in USA Today and then a lengthy New York Times story on Sunday about Shkreli and how his company, Turing Pharmaceuticals, raised the price of a 62-year-old drug Daraprim from $13...